Wanbangde Pharmaceutical Holdings Group (002082.SZ) subsidiary WP107's multi-dose clinical study has received ethical approval.

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that WP107, a new drug for the treatment of generalized myasthenia gravis independently developed by its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Wenzhou Medical University Affiliated Yuying Children's Hospital to conduct a multi-dose escalation clinical trial in healthy participants. Huperzine A, as a highly selective acetylcholinesterase inhibitor, has demonstrated significant improvement in MG symptoms in previous clinical trials. WP107, as an oral solution of Huperzine A, is expected to provide a clinical option for global MG patients that is clearly effective, has fewer adverse reactions, is suitable for long-term use, and is more patient-friendly for those with swallowing difficulties, while also exhibiting good synergistic therapeutic effects with emerging biological agents such as FcRn blockers and complement inhibitors. The approval received from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Wenzhou Medical University Affiliated Yuying Children's Hospital aims to evaluate the pharmacokinetic characteristics, safety, and tolerance of multiple doses of Huperzine A oral solution in healthy trial participants.